Company Overview: Inovio

Industry News

2 Jan

Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater...

Read more

29 Nov

Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.  VGX-3100, Inovio’s lead product now in a pivotal phase 3 trial,...

Read more

27 Nov

Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. The combination therapies resulted in robust anti-tumor effects and showed significant improvement in...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address